Nitric oxide synthases, cyclooxygenase-2, nitrotyrosine, and angiogenesis in chondrosarcoma and their relation to prognosis

Journal of Bone and Joint Surgery

Volumn 92, Issue 8, 2010, Pages 1738-1746

  Nakagawa, Suely Akiko ^a   Lopes, Ademar ^a   De Carvalho, André Lopes ^b   Rossi, Benedito Mauro ^a   Da Cunha, Isabela Werneck ^a   Soares, Fernando Augusto ^a   Chung, Wu Tu ^a   Alves, Lucíola Assunção ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; CD34 ANTIGEN; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; 3-NITROTYROSINE; DRUG DERIVATIVE; NITRIC OXIDE SYNTHASE; TUMOR MARKER; TYROSINE;

ADOLESCENT; ADULT; ANGIOGENESIS; ARTICLE; CANCER GRADING; CHILD; CHONDROSARCOMA; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SURVIVAL RATE; TISSUE MICROARRAY; BIOSYNTHESIS; BONE TUMOR; CANCER STAGING; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PREDICTION AND FORECASTING; SURVIVAL;

ANTIGENS, CD34; BONE NEOPLASMS; CHONDROSARCOMA; CYCLOOXYGENASE 2; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE SYNTHASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 77955296367     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.H.00717     Document Type: Article

References (64)

1. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995;55:727-30.
2. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995;72:41-4.
3. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, Ando M. Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res. 1997;88:1190-8. (Pubitemid 28048266)
4. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000;6:4768-75. (Pubitemid 32110418)
5. Hida T, Yatabe Y, Achiwa H, Muramatsu H, Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T, Takahashi T. Increased expression of cyclooxygenase-2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998;58:3761-4.
6. Hara A, Okayasu I. Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol. 2004;108:43-8.
7. Uefuji K, Ichikura T, Mochizuki H, Shinomiya N. Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. J Surg Oncol. 1998;69:168-72. (Pubitemid 28549893)
8. Endo M, Matsumura T, Yamaguchi T, Yamaguchi U, Morimoto Y, Nakatani F, Kawai A, Chuman H, Beppu Y, Shimoda T, Hasegawa T. Cyclooxygenase-2 overexpression associated with a poor prognosis in chondrosarcomas. Hum Pathol. 2006;37:471-6.
9. Jiang X, Dutton CM, Qi W, Block JA, Brodt P, Durko M, Scully SP. Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma. J Orthop Res. 2003;21:1063-70.
10. Hall PS, Cameron DA. Current perspective-trastuzumab. Eur J Cancer. 2009;45:12-8.
11. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: Herceptin and beyond. Eur J Cancer. 2008;44:2806-12.
12. Hicks DG, Kulkarni S. Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testing. Arch Pathol Lab Med. 2008;132:1008-15.
13. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J. 1992;6:3051-64.
14. Bittrich H, Mátzig AK, Kráker I, Appel KE. NO2-induced DNA single strand breaks are inhibited by antioxidative vitamins in V79 cells. Chem Biol Interact. 1993;86:199-211. (Pubitemid 23131889)
15. Kennedy LJ, Moore K Jr, Caulfield JL, Tannenbaum SR, Dedon PC. Quantitation of 8-oxoguanine and strand breaks produced by four oxidizing agents. Chem Res Toxicol. 1997;10:386-92.
16. Landino LM, Crews BC, Timmons MD, Morrow JD, Marnett LJ. Peroxynitrite, the coupling product of nitric oxide and superoxide, activates prostaglandin biosynthesis. Proc Natl Acad Sci U S A. 1996;93:15069-74.
17. Wink DA, Kasprzak KS, Maragos CM, Elespuru RK, Misra M, Dunams TM, Cebula TA, Koch WH, Andrews AW, Allen JS, Keefer LK. DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science. 1991;254:1001-3. (Pubitemid 21917428)
18. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci U S A. 1992;89:3030-4.
19. Laval F, Wink DA. Inhibition by nitric oxide of the repair protein, O6-methylguanine-DNA-methyltransferase. Carcinogenesis. 1994;15:443-7.
20. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994;305:253-64.
21. Wink DA, Laval J. The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo. Carcinogenesis. 1994;15:2125-9.
22. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994;54:1352-4.
23. Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS, Weissler MC. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg. 1995;113:541-9.
24. Rajnakova A, Goh PM, Chan ST, Ngoi SS, Alponat A, Moochhala S. Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis. 1997;18:1841-5. (Pubitemid 28134694)
25. Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res. 1998;58:334-41. (Pubitemid 28047076)
26. Weninger W, Rendl M, Pammer J, Mildner M, Tschugguel W, Schneeberger C, Stürzl M, Tschachler E. Nitric oxide synthases in Kaposi's sarcoma are expressed predominantly by vessels and tissue macrophages. Lab Invest. 1998;78:949-55.
27. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 1998;58:2929-34.
28. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urol. 1999;161:630-4.
29. Mendes RV, Martins AR, de Nucci G, Murad F, Soares FA. Expression of nitric oxide synthase isoforms and nitrotyrosine immunoreactivity by B-cell non-Hodgkin's lymphomas and multiple myeloma. Histopathology. 2001;39:172-8.
30. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis. 1996;55:7-20.
31. Kröncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytotoxicity versus cytoprotection - how, why, when, and where? Nitric Oxide. 1997;1:107-20.
32. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-7. (Pubitemid 20224299)
33. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol. 1990;101:325-8. (Pubitemid 20224299)
34. Xie K, Dong Z, Fidler IJ. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J Leukoc Biol. 1996;59:797-803. (Pubitemid 26238474)
35. Hajri A, Metzger E, Vallat F, Coffy S, Flatter E, Evrard S, Marescaux J, Aprahamian M. Role of nitric oxide in pancreatic tumour growth: in vivo and in vitro studies. Br J Cancer. 1998;78:841-9.
36. Andrade SP, Hart I, Piper P. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol. 1992;107:1092-5.
37. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res. 1994;85:331-4.
38. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol. 1992;262(2 Pt 2):H611-5.
39. Dickens DS, Kozielski R, Khan J, Forus A, Cripe TP. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol. 2002;5:356-64.
40. Kasper HU, Wolf H, Drebber U, Wolf HK, Kern MA. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in pancreatic adenocarcinoma: correlation with microvessel density. World J Gastroenterol. 2004;10:1918-22. (Pubitemid 39029293)
41. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-16. Erratum in: Cell. 1998;94:following 271.
42. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol. 2004;31(2 Suppl 7):2-11. (Pubitemid 38879409)
43. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002;33:213-9. (Pubitemid 34298737)
44. Gallo O, Masini E, Bianchi B, Bruschini L, Paglierani M, Franchi A. Prognostic significance of cyclooxygenase-2 pathway and angiogenesis in head and neck squamous cell carcinoma. Hum Pathol. 2002;33:708-14. (Pubitemid 34953350)
45. Andrews RG, Singer JW, Bernstein ID. Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood. 1986;67:842-5.
46. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, Sutherland DR, Baker MA, Greaves MF. Expression of the CD34 gene in vascular endothelial cells. Blood. 1990;75:2417-26. (Pubitemid 20202322)
47. Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics. Tumours of soft tissue and bone. World Health Organization classification of tumours, vol 5. Lyon, France: IARC Press; 2002. p 226-58.
48. Cunha IW, Lopes A, Falzoni R, Soares FA. Sarcomas often express constitutive nitric oxide synthases (NOS) but infrequently inducible NOS. Appl Immunohistochem Mol Morphol. 2006;14:404-10.
49. Dorfman HD, Czerniak B. Bone tumors. St. Louis: CV Mosby; 1998. Malignant cartilage tumors; p 353-440.
50. Staging of musculoskeletal neoplasms. Musculoskeletal Tumor Society. Skeletal Radiol. 1985;13:183-94.
51. Rizzo M, Ghert MA, Harrelson JM, Scully SP. Chondrosarcoma of bone: analysis of 108 cases and evaluation for predictors of outcome. Clin Orthop Relat Res. 2001;391:224-33.
52. Healey JH, Lane JM. Chondrosarcoma. Clin Orthop Relat Res. 1986;204:119-29.
53. Gitelis S, Bertoni F, Picci P, Campanacci M. Chondrosarcoma of bone. The experience at the Istituto Ortopedico Rizzoli. J Bone Joint Surg Am. 1981;63:1248-57.
54. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, Jennings LC. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81:326-38.
55. Reith JD, Horodyski MB, Scarborough MT. Grade 2 chondrosarcoma: stage I or stage II tumor? Clin Orthop Relat Res. 2003;415:45-51.
56. Di Cesare PE, Carlson CS, Attur M, Kale AA, Abramson SB, Della Valle C, Steiner G, Amin AR. Up-regulation of inducible nitric oxide synthase and production of nitric oxide by the Swarm rat and human chondrosarcoma. J Orthop Res. 1998;16:667-74. (Pubitemid 29021896)
57. Doi K, Akaike T, Horie H, Noguchi Y, Fujii S, Beppu T, Ogawa M, Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer. 1996;77(8 Suppl):1598-604.
58. Furumatsu T, Nishida K, Kawai A, Namba M, Inoue H, Ninomiya Y. Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth. Int J Cancer. 2002;97:313-22.
59. Ayala G, Liu C, Nicosia R, Horowitz S, Lackman R. Microvasculature and VEGF expression in cartilaginous tumors. Hum Pathol. 2000;31:341-6.
60. Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, Stenson WF. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology. 1996;111:871-85.
61. Ischiropoulos H. Biological tyrosine nitration: a pathophysiological function of nitric oxide and reactive oxygen species. Arch Biochem Biophys. 1998;356:1-11.
62. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, Hayashi H, Ono T, Yamanoi A, Kohno H, Nagasue N. Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 2001;7:1325-32.
63. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW, Rhee JC. Role of cyclooxygenase-2 and inducible nitric oxide synthase in pancreatic cancer. J Gastroenterol Hepatol. 2002;17:914-21.
64. Sulh MA, Greco MA, Jiang T, Goswami SB, Present D, Steiner G. Proliferation index and vascular density of giant cell tumors of bone: are they prognostic markers? Cancer. 1996;77:2044-51.